Rodriguez L F, Smolik L M, Zbehlik A J
Stanford University Medical Center, CA.
Ann Pharmacother. 1994 May;28(5):643-9. doi: 10.1177/106002809402800515.
To report a case of benzocaine-induced inethemoglobinemia and present a review of the related literature.
An 83-year-old man received benzocaine topical anesthesia 600 mg prior to intubation for resection of a thyroid adenoma. The patient became severely cyanotic after induction of anesthesia. After a negative workup for common causes of cyanosis. blood co-oximetry analysis revealed a methemoglobin concentration of 54.1 percent. Intravenous methylene blue reversed the methemoglobinemia, although delayed recurrence 20 h later necessitated readministration of intravenous methylene blue. The patient developed cardiovascular instability and severe neurologic depression requiring prolonged ventilatory support.
Methemoglobinemia can result from exposure to a number of drugs including benzocaine. Cyanosis, neurological and cardiac dysfunction may result when methemoglobin concentrations exceed 30 percent. Clinical diagnosis is made on the presentation of cyanosis unresponsive to oxygen administration and a distinctive arterial blood brown color; laboratory confirmation is by cooximetry. Treatment of symptomatic methemoglobinemia is by intravenous methylene blue (1-2 mg/kg) administration. Fifty-four cases of benzocaine-induced methemoglobinemia have been reported in the literature. Intubation, endoscopy/bronchoscopy, and ingestion were the most common procedures in which benzocaine administration produced methemoglobinemia. Infants and the elderly were more likely to develop toxic methemoglobinemia after benzocaine exposure. Other risk factors included genetic reductase deficiencies, exposure to high doses of anesthetic, and presence of denuded skin and mucous membranes.
Because of the potential for severe complications, methemoglobinemia should be corrected promptly in compromised patients and those with toxic benzocaine concentrations. The possibility of masking symptoms during general anesthesia carries special risk of use of this agent in the preanesthesia setting.
报告一例苯佐卡因诱发的高铁血红蛋白血症病例,并对相关文献进行综述。
一名83岁男性在甲状腺腺瘤切除插管前接受了600mg苯佐卡因局部麻醉。麻醉诱导后患者出现严重发绀。在对常见的发绀原因进行检查结果为阴性后,血液共血氧定量分析显示高铁血红蛋白浓度为54.1%。静脉注射亚甲蓝逆转了高铁血红蛋白血症,尽管20小时后复发延迟需要再次静脉注射亚甲蓝。患者出现心血管不稳定和严重的神经抑制,需要长时间的通气支持。
高铁血红蛋白血症可由接触多种药物引起,包括苯佐卡因。当高铁血红蛋白浓度超过30%时,可能会导致发绀、神经和心脏功能障碍。临床诊断依据为吸氧后仍无法缓解的发绀表现以及动脉血呈现独特的棕色;实验室确诊通过共血氧定量法。有症状的高铁血红蛋白血症的治疗方法是静脉注射亚甲蓝(1-2mg/kg)。文献中已报道54例苯佐卡因诱发的高铁血红蛋白血症病例。插管、内镜检查/支气管镜检查和摄入是苯佐卡因给药导致高铁血红蛋白血症最常见的操作。婴儿和老年人在接触苯佐卡因后更易发生中毒性高铁血红蛋白血症。其他风险因素包括遗传还原酶缺乏、高剂量麻醉剂暴露以及皮肤和黏膜剥脱。
由于存在严重并发症的可能性,对于病情不佳的患者以及苯佐卡因浓度中毒的患者,应及时纠正高铁血红蛋白血症。在麻醉前使用该药物时,全身麻醉期间掩盖症状的可能性存在特殊风险。